ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
View Patent ↗This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
1. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
3. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
4. The pharmaceutical composition of claim 3 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
5. A tablet comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
or a pharmaceutically acceptable salt thereof, and
at least one pharmaceutically acceptable excipient.
6. A tablet of claim 5 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X
7. A tablet of claim 5 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent.
8. A tablet of claim 6 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent.